Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1540 - The routine real-life use of trabectedin (T) in patients with advanced soft tissue sarcoma (STS) across Europe: an analysis of overall vs. per country results from Y-IMAGE study


11 Sep 2017


Poster display session


Cytotoxic Therapy;  Soft Tissue Sarcomas


Nicolas Penel


Annals of Oncology (2017) 28 (suppl_5): v521-v538. 10.1093/annonc/mdx387


N. Penel1, C. Benson2, B. Kasper3, A. Buonadonna4

Author affiliations

  • 1 Medical Oncology, Centre Oscar Lambret, 59020 - Lille/FR
  • 2 Medical Oncology, Royal Marsden Hospital NHS Foundation Trust, SW3 6JJ - London/GB
  • 3 Interdisziplinäres Tumorzentrum, Universitätsklinikum Mannheim, 68167 - Mannheim/DE
  • 4 Medical Oncology, Centro di Riferimento Oncologico, 33081 - Aviano/IT


Abstract 1540


The prospective, non-interventional, phase IV Y-IMAGE study evaluated the use of T in real-life clinical practice across Europe in patients with advanced STS.


Data from adult STS patients treated with T 1.5 mg/m2 given as 24-h i.v. infusion q3w were collected. Patients must have received at least 1 cycle of T and currently be on T treatment. The primary endpoint was progression-free survival (PFS) as defined by investigators. The analyses were conducted in the overall population (OP) and separately in countries with the highest recruiting rate to cover inter-country variations: France (F), Germany (G), Italy (I) and the UK.


A total of 218 patients from 41 centers and 9 European countries were evaluated. Demographics and baseline characteristics of patients recruited in the 4 countries of interest were well-balanced and comparable to those observed in OP. Patients received a median of 6 cycles of T (range: 1-44), mostly on an outpatient basis (n = 132; 60.6%). Across all centers the median cycle duration, and median dose and dose intensity were similar to those observed in OP. Analysis of PFS data showed a similar outcome in G (median PFS: 5.9 months) to that observed in OP (5.9 months), and a rather higher PFS in the UK (8.3 months), F (7.6 months) and I (6.8 months). The patients from the UK received the highest median number of cycles (10.5) and cumulative dose of T (26.2 mg) as compared to F, G and I. This was associated with favorable efficacy outcomes in those patients, particularly in terms of improved PFS (8.3 months), responses (ORR: 38.5%; DCR: 84.6%) and a high growth modulation index of 2.3. T treatment resulted in a comparable median overall survival in all patients (21.3 months), being somewhat larger among patients treated in sites across G (27.3 months). Febrile neutropenia (2.3% of patients), neutropenia, nausea, and pneumonia (1.4% each) were the most common T-related grade 3/4 adverse drug reactions.Table:


Full analysis set, n (%)
France (n = 26)Germany (n = 29)Italy (n = 69)UK (n = 26)Overall population (n = 218)
Age at study entry (years); Median (range)58.5 (22-77)58 (23-79)59 (26-79)56.6 (25-73)58.0 (21.0-79.0)
Female15(57.7)15 (51.7)44 (63.8)13 (50.0)123 (56.4)
Histology (≥10% of patients)
Leiomyosarcoma11 (42.3)11 (37.9)29 (42.0)16 (61.5)92 (42.2%)
Liposarcoma5 (19.2)23 (33.3)7 (26.9)51 (23.4)
Synovial sarcoma4 (15.4)5 (17.2)23 (10.6%)
Cycles per patient Median (range)5.5 (2-29)6.0 (2-18)6.0 (1-30)10.5 (1-44)6.0 (1-44)
Cumulative dose received mg/patient12.1 (3.7-48.2)20.8 (5.6-51.0)14.3 (1.9-60)26.2 (3-116.4)14.7 (1.8-116.4)
Cycle duration (days)24.9 (21-41)26.8 (21-44.4)23.7 (20.5-32.5)24.2 (21-30.6)24.1 (20-47.5)
Dose intensity (mg/m2/week)0.7 (0.2-1.0)0.6 (0.4-1.1)0.6 (0.3-1.0)0.7 (0.5-1.0)0.7 (0.2-1.1)
Median PFS (months) [95% Confidence interval]7.6 [3.3-NR]5.9 [3.4-11.2]6.8 [3.4-10.2]8.3 [5.5-11.4]5.9 [4.9-7.8]
Objective response rate (ORR) (Complete + partial response) [95% Confidence interval]6 (23.1) [9.0-43.6]9 (31.0) [15.3-50.8]15 (21.7) [12.7-33.3]10 (38.5) [20.2-59.4]58 (26.6) [20.9-33.0]
Disease control rate (DCR) (ORR + stable disease) [95% Confidence interval]17 (65.4) [44.3-82.8]20 (69.0) [49.2-84.7]48 (69.6) [57.3-80.1]22 (84.6) [65.1-95.6]143 (65.6) [58.9-71.9]
Time to progression (TTP), median (months) [95% Confidence interval]7.8 [4.9-NR]6.9 [4.2-11.2]6.8 [3.4-10.2]8.3 [5.5-11.4]5.9 [4.9-8.1]
Overall survival (OS), median (months) [95% Confidence interval]20.3 [9.6-NR]27.3 [9.2-NR]22.5 [19.0-NR]20.0 [18.2-23.6]21.3 [18.8-24.3]
Growth modulation index (GMI), median a Range (min-max) ≤1.1, n (%) >1.1 -


In real-life setting T confers meaningful benefits to patients with multiple STS histotypes with a manageable safety profile regardless of small country variations.

Clinical trial identification

Y-IMAGE; ET-D-020-12

Legal entity responsible for the study





C. Benson: Honoraria from PharmaMar for speaking and travel grants. B. Kasper: Honoraria from PharmaMar. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.